Amgen Inc. or Bausch Health Companies Inc.: Who Invests More in Innovation?

Innovation Investment: Amgen Inc. vs. Bausch Health Companies Inc.

In the competitive landscape of the pharmaceutical industry, innovation is key. Over the past decade, Amgen Inc. has consistently outpaced Bausch Health Companies Inc. in research and development (R&D) spending. From 2014 to 2023, Amgen's R&D expenses have grown by approximately 11%, peaking in 2021 with a 35% higher investment than its 2014 figures. In contrast, Bausch Health's R&D spending, while showing a steady increase, remains significantly lower, with its highest expenditure in 2023 being just 13% of Amgen's peak in 2021.

This trend highlights Amgen's commitment to innovation, investing nearly nine times more on average annually than Bausch Health. Such financial dedication to R&D not only underscores Amgen's strategic focus on pioneering new treatments but also positions it as a leader in pharmaceutical advancements. As the industry evolves, these investments could be pivotal in shaping future healthcare solutions.